The story of Viagra presents a complex case for observers in the medicinal sector. While initially a phenomenal success, producing huge profits, the patent lapse and the subsequent arrival of cheaper alternatives have considerably affected earnings. This poses questions about the future sustainability of analogous drug developments and suggests tha